ATE348632T1 - Prion protein peptide und deren verwendung - Google Patents
Prion protein peptide und deren verwendungInfo
- Publication number
- ATE348632T1 ATE348632T1 AT00941708T AT00941708T ATE348632T1 AT E348632 T1 ATE348632 T1 AT E348632T1 AT 00941708 T AT00941708 T AT 00941708T AT 00941708 T AT00941708 T AT 00941708T AT E348632 T1 ATE348632 T1 AT E348632T1
- Authority
- AT
- Austria
- Prior art keywords
- prion protein
- protein peptides
- prp
- therapeutic
- antibodies specific
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000029797 Prion Human genes 0.000 title 1
- 108091000054 Prion Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000024777 Prion disease Diseases 0.000 abstract 1
- 238000005202 decontamination Methods 0.000 abstract 1
- 230000003588 decontaminative effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14063499P | 1999-06-23 | 1999-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE348632T1 true ATE348632T1 (de) | 2007-01-15 |
Family
ID=22492135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00941708T ATE348632T1 (de) | 1999-06-23 | 2000-06-23 | Prion protein peptide und deren verwendung |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1194164B8 (de) |
JP (1) | JP2003521477A (de) |
CN (1) | CN1370078A (de) |
AT (1) | ATE348632T1 (de) |
AU (1) | AU783484B2 (de) |
CA (1) | CA2377648A1 (de) |
DE (1) | DE60032486T2 (de) |
ES (1) | ES2278617T3 (de) |
HK (1) | HK1048955A1 (de) |
MX (1) | MXPA01013186A (de) |
NZ (1) | NZ516240A (de) |
WO (1) | WO2000078344A1 (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041807B1 (en) | 1999-06-23 | 2006-05-09 | Caprion Pharmaceuticals, Inc. | Antibodies to a YYX epitope of a mammalian prion protein |
CA2413742A1 (en) * | 2000-06-26 | 2002-01-03 | Universitat Zurich | Prion-binding activity in serum and proteins |
US7303907B2 (en) | 2001-01-08 | 2007-12-04 | Health Protection Agency | Degradation and detection of TSE infectivity |
GB2376071A (en) * | 2001-05-31 | 2002-12-04 | Mini Agriculture & Fisheries | Method for typing a TSE strain |
GB2379737A (en) * | 2001-09-05 | 2003-03-19 | Univ Geneve | Diagnostic method for spongiform encephalopathy disease |
WO2003040685A2 (en) * | 2001-11-09 | 2003-05-15 | King's College London | Diagnosis demyelinating or spongiform disease |
AU2003205623A1 (en) * | 2002-01-18 | 2003-07-30 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
EP2301959A3 (de) | 2002-04-09 | 2013-03-13 | The Scripps Research Institute | Mit motiven transplantierte hybrid-polypeptide und verwendungen davon |
EP1382971A1 (de) * | 2002-07-17 | 2004-01-21 | Pepscan Systems B.V. | Nachweis von Prion Erkrankung |
US20040072236A1 (en) | 2002-09-27 | 2004-04-15 | Neil Cashman | PrPSc -interacting molecules and uses thereof |
AU2003274368B2 (en) * | 2002-10-30 | 2008-11-20 | Proteome Sciences Plc. | Diagnostic method for transmissible spongiform encephalopathies (prion diseases) |
GB0227886D0 (en) | 2002-11-29 | 2003-01-08 | Medical Res Council | Prion inhibition |
EP2317317B1 (de) * | 2002-12-03 | 2014-11-26 | North Carolina State University | Prionen-Protein-Liganden und Verfahren zu deren Verwendung |
CN1297663C (zh) * | 2003-05-07 | 2007-01-31 | 中国科学院微生物研究所 | 一类重组基因产生的朊蛋白(PrPC)融合变构体及其用途 |
WO2005016127A2 (en) | 2003-08-13 | 2005-02-24 | Chiron Corporation | Prion-specific peptide reagents |
EP1668369B1 (de) | 2003-08-20 | 2016-01-06 | ProMIS Neurosciences Inc. | Epitopschutztest und verfahren zum nachweis von proteinkonformationen |
RU2251699C1 (ru) * | 2003-09-25 | 2005-05-10 | Киселев Всеволод Иванович | Способ ранней и доклинической диагностики цервикального рака |
US7482172B2 (en) | 2005-09-19 | 2009-01-27 | Ortho-Clinical Diagnostics, Inc. | Peptides for discrimination of prions |
AU2005209592B2 (en) | 2004-09-30 | 2012-07-12 | Ortho-Clinical Diagnostics, Inc. | Peptides for discrimination of prions |
NZ594844A (en) | 2005-09-09 | 2013-04-26 | Novartis Ag | Prion-specific peptoid reagents |
US7794692B2 (en) | 2005-12-02 | 2010-09-14 | Amorfix Life Sciences Ltd. | Methods and compositions for detecting amyotrophic lateral sclerosis |
US7887803B2 (en) | 2005-12-02 | 2011-02-15 | Amorfix Life Sciences | Methods and compositions to treat misfolded-SOD1 mediated diseases |
CA2642848C (en) | 2006-03-03 | 2016-07-12 | Amorfix Life Sciences Ltd. | Methods and compositions to treat and detect misfolded-sod1 mediated diseases |
US7601506B2 (en) | 2006-07-28 | 2009-10-13 | Idexx Laboratories, Inc. | Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies |
AU2009239651B2 (en) | 2008-04-25 | 2013-12-12 | University Of Saskatchewan | Prion epitopes and methods of use thereof |
EP2128618A1 (de) * | 2008-05-30 | 2009-12-02 | Prion Diagnostica S.r.l. | Verfahren zur Kontrolle der Präsenz von pathogenen Wirkstoffen in biologischen Flüssigkeiten durch nanostrukturierte Stoffe |
DK2342220T3 (da) * | 2008-10-06 | 2021-08-09 | Univ British Columbia | Metoder og systemer til forudsigelse af misfoldede proteinepitoper |
US9110024B2 (en) | 2009-03-25 | 2015-08-18 | Los Alamos National Security, Llc | Fiber optical asssembly for fluorescence spectrometry |
JP2012522222A (ja) * | 2009-03-25 | 2012-09-20 | ロス アラモス ナショナル セキュリティー,エルエルシー | 感染因子の急速な生前検出 |
TWI419711B (zh) * | 2010-07-27 | 2013-12-21 | Univ Nat Changhua Education | Tyrosinase polypeptide inhibitor |
CN102492018A (zh) * | 2010-07-27 | 2012-06-13 | 萧乃文 | 酪氨酸酶多肽抑制剂 |
WO2012099884A1 (en) * | 2011-01-18 | 2012-07-26 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for amplification and detection of prions |
JP6430373B2 (ja) * | 2012-06-12 | 2018-11-28 | プロミス、ニューロサイエンシズ、インコーポレイテッドPromis Neurosciences Inc. | ミスフォールドプリオンタンパク質を標的とする抗体および複合体 |
US9809620B2 (en) | 2013-04-30 | 2017-11-07 | University Of Saskatchewan | Prion disease-specific epitopes and methods of use thereof |
CN108409865A (zh) * | 2018-01-19 | 2018-08-17 | 鄞州出入境检验检疫局综合技术服务中心 | 特异性双酚a羊多克隆抗体及其应用 |
EP3966227A1 (de) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ246059A (en) * | 1991-12-03 | 1995-08-28 | Proteus Molecular Design | Synthetic polypeptides with at least one antigenic site of a prion protein, methods of their use and manufacture, antibodies thereto, compositions and kits |
WO1993023432A1 (en) * | 1992-05-15 | 1993-11-25 | New York University | Soluble prion polypeptides, and methods for detecting and purifying thereof |
CA2231409C (en) * | 1995-09-14 | 2003-02-11 | The Regents Of The University Of California | Antibodies specific for native prpsc |
US5750361A (en) * | 1995-11-02 | 1998-05-12 | The Regents Of The University Of California | Formation and use of prion protein (PRP) complexes |
US5891641A (en) * | 1997-02-21 | 1999-04-06 | The Regents Of The University Of California | Assay for disease related conformation of a protein |
EP0861900A1 (de) * | 1997-02-21 | 1998-09-02 | Erziehungsdirektion Of The Canton Zurich | Immunologischer Nachweis von Prionen |
US6165784A (en) * | 1997-10-14 | 2000-12-26 | The United States Of America As Represented By The Secretary Of Agriculture | Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies |
-
2000
- 2000-06-23 WO PCT/US2000/017455 patent/WO2000078344A1/en active IP Right Grant
- 2000-06-23 EP EP00941708A patent/EP1194164B8/de not_active Expired - Lifetime
- 2000-06-23 MX MXPA01013186A patent/MXPA01013186A/es active IP Right Grant
- 2000-06-23 CA CA002377648A patent/CA2377648A1/en not_active Abandoned
- 2000-06-23 AT AT00941708T patent/ATE348632T1/de not_active IP Right Cessation
- 2000-06-23 JP JP2001504406A patent/JP2003521477A/ja active Pending
- 2000-06-23 CN CN00811803A patent/CN1370078A/zh active Pending
- 2000-06-23 AU AU56375/00A patent/AU783484B2/en not_active Ceased
- 2000-06-23 ES ES00941708T patent/ES2278617T3/es not_active Expired - Lifetime
- 2000-06-23 DE DE60032486T patent/DE60032486T2/de not_active Expired - Lifetime
- 2000-06-23 NZ NZ516240A patent/NZ516240A/en not_active IP Right Cessation
-
2003
- 2003-02-20 HK HK03101306.4A patent/HK1048955A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
DE60032486T2 (de) | 2007-08-16 |
EP1194164A1 (de) | 2002-04-10 |
WO2000078344A1 (en) | 2000-12-28 |
HK1048955A1 (zh) | 2003-04-25 |
DE60032486D1 (de) | 2007-02-01 |
EP1194164A4 (de) | 2004-09-08 |
EP1194164B1 (de) | 2006-12-20 |
AU783484B2 (en) | 2005-11-03 |
AU5637500A (en) | 2001-01-09 |
NZ516240A (en) | 2005-11-25 |
WO2000078344A8 (en) | 2001-11-15 |
ES2278617T3 (es) | 2007-08-16 |
CN1370078A (zh) | 2002-09-18 |
EP1194164B8 (de) | 2007-03-21 |
MXPA01013186A (es) | 2002-08-12 |
CA2377648A1 (en) | 2000-12-28 |
JP2003521477A (ja) | 2003-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE348632T1 (de) | Prion protein peptide und deren verwendung | |
DE122012000001I1 (de) | Humane antikorper gegen CTLA-4 und deren verwendungen. | |
HUP9802212A2 (hu) | Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok | |
CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
DE60239931D1 (de) | Kombinationstherapie | |
TR200301846T2 (tr) | Cripto bloke edici Antikorlar ve bu antikorların kullanımları. | |
ATE385806T1 (de) | Fusionsproteine | |
TR200401638T2 (tr) | Bir reseptöre bağlanan peptidler ve bileşikler. | |
DE60331049D1 (de) | Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden | |
HK1069316A1 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
MX2007013626A (es) | Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos. | |
EP1200124A4 (de) | Immunglobulin fusionsproteine | |
DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
BR9707819A (pt) | Imunogenos peptidicos | |
DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
ATE396205T1 (de) | Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe | |
DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
DE69714451D1 (de) | Prionbindende proteine und deren verwendungen | |
YU68602A (sh) | Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje | |
DE69725754D1 (de) | Eingekapselte Antikörper-produzierende Zellen | |
ATE368687T1 (de) | Thrombopoietinproteine mit verbesserten eigenschaften | |
ID23184A (id) | Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi | |
DE60229924D1 (de) | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten | |
ATE528392T1 (de) | Neues protein und dessen dns | |
DE50210279D1 (de) | Screeningverfahren mit bnpi und dnpi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |